Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

15.67
+0.37002.42%
Post-market: 15.700.0300+0.19%19:33 EDT
Volume:1.78M
Turnover:27.35M
Market Cap:1.48B
PE:-4.97
High:15.71
Open:15.24
Low:14.97
Close:15.30
52wk High:16.15
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:0.79
T/O Rate:2.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:13.98
PE(LYR):-4.63

Loading ...

FDA's Makary on Replimune's Drug Says IF the Clinical Trials Show That It Works, It's Going to GET Approved - CNBC

THOMSON REUTERS
·
May 05

Replimune to present IGNYTE trial survival data at ASCO annual meeting

Reuters
·
Apr 27

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
Apr 27

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Reuters
·
Apr 23

Replimune rises after Wall Street Journal editorial defending RP1

TIPRANKS
·
Apr 22

Replimune Group (REPL) was downgraded to a Hold Rating at Leerink Partners

TIPRANKS
·
Apr 15

NASD Most Active Issues

Dow Jones
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune

Reuters
·
Apr 14

FDA Rejection Sparks Questions On Replimune Drug Approval Path

Benzinga_recent_news
·
Apr 14

Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%. -- Barrons.com

Dow Jones
·
Apr 13

BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma

Reuters
·
Apr 13

Replimune Group Facing 'Significant Risk' on RP1's Ongoing Phase 3 Study, Wedbush Says

MT Newswires Live
·
Apr 13

Replimune Shares Plummet to All-Time Low as FDA Rejection Muddies Path Forward

Dow Jones
·
Apr 13

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:52 AM

Reuters
·
Apr 13

Replimune Group Cut to Neutral From Overweight by Cantor Fitzgerald

Dow Jones
·
Apr 13

Replimune Shares Decline 66.3% as at Least Six Brokerages Downgrade Stock After Co's Drug Fails to Win FDA Nod

THOMSON REUTERS
·
Apr 13

BUZZ-Street View: Tough path ahead for Replimune after second FDA setback on melanoma drug

Reuters
·
Apr 13

Top Premarket Decliners

MT Newswires Live
·
Apr 13

Replimune Group Inc : Bmo Cuts to Underperform From Market Perform; Cuts Target Price to $1 From $11

THOMSON REUTERS
·
Apr 13

Wedbush Downgrades Replimune Group to Neutral From Outperform, Cuts Price Target to $2 From $19

MT Newswires Live
·
Apr 13